Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02425566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Jul 2026 → Jul 2028
See other at-risk trials from Vanderbilt University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 2026 to Jul 2028
    • Study completion pushed from Aug 2026 to Aug 2028
    v17
  2. Primary completion date: Jul 2025 to Jul 2026
    • Study completion date: Aug 2025 to Aug 2026
    v16
  3. Primary completion date: Jul 2024 to Jul 2025
    • Study completion date: Aug 2024 to Aug 2025
    v15
  4. Primary completion date: Jul 2023 to Jul 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Aug 2023 to Aug 2024
    • Site details revised
    v14
  5. Primary completion date: Jul 2022 to Jul 2023
    • Study completion date: Aug 2022 to Aug 2023
    v13
Show 11 earlier versionsHide 11 earlier versions
  1. Primary completion date: Jul 2021 to Jul 2022
    • Study completion date: Aug 2021 to Aug 2022
    v12
  2. Trial status: Suspended to Recruiting
    • Site details revised
    v11
  3. Trial status: Recruiting to Suspended Sponsor's reason: Recruitment is temporarily suspended due to COVID-19 outbreak
    • Site details revised
    v10
  4. Primary completion date: Jul 2020 to Jul 2021
    • Study completion date: Aug 2020 to Aug 2021
    v9
  5. Site contact updatedv8
  6. 2 versions Re-verified since Aug 17, 2017, no change to tracked fieldsv6-v7
  7. Site contact updatedv5
  8. Phase: Not applicable to Phase 1
    • Primary completion date: Jul 2018 to Jul 2020
    • Study completion date: Aug 2018 to Aug 2020
    v4
  9. Interventions: Trimethaphan (Drug) to Nitroglycerin (Drug), Trimethaphan (Drug)
    • Eligibility criteria expanded, about 12 words
    • Study description expanded, about 41 words
    • Study arms: 1 to 2
    v3
  10. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to better understand the role of the abdominal veins (splanchnic capacitance) and the sympathetic nervous system in human hypertension. The investigators will test the hypothesis that constriction of abdominal veins due to sympathetic activation contributes to human hypertension. Splanchnic capacitance will be assessed in normotensive and hypertensive subjects at baseline and during acute blockade of the autonomic nervous system.
Trial Details
NCT Number NCT02425566
Lead Sponsor Vanderbilt University
Conditions
(from sponsor)		 Hypertension
Related terms Hypertension
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov